Phase II study of cetuximab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2019
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms JACCRO CC-08
- 08 Mar 2019 Status changed from active, no longer recruiting to completed.
- 15 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2016 Primary endpoint (Progression-free survival rate) has been met.